Steve has over 25 years of toxicology experience, including key roles as a drug development team representative for multiple therapeutic areas and in developing and implementing experimental and regulatory strategies to support development of promising preclinical drug candidates. In addition to cofounding XPD Holdings, Steve is a Partner and Chief Scientific Officer at INDS, Inc., an innovative nonclinical drug development consulting group.

Jim has 25 years of nonclinical drug safety research and development experience, including tactical and strategic support of nonclinical development projects. Jim has significant experience in the regulatory toxicology field (US, EU, and Japan), and has contributed to over 100 IND and NDA submissions. In addition to cofounding XPD Holdings, Jim is a Partner and President at INDS, Inc., an innovative nonclinical drug development consulting group.

A founding member of XPD Holdings, Marc previously led the Safety Pharmacology Group at Pfizer, Ann Arbor. Marc was a key member of numerous Discovery and Development project teams at Pfizer and he has extensive experience evaluating the pharmacologic and toxicologic activity of drug candidates. Marc is also a founder and Chief Development Officer at INDS, Inc., an innovative drug development consulting group in Ann Arbor, MI.